NCT05625971View on ClinicalTrials.gov

Non-invasive MRD Assessment in Multiple Myeloma

RecruitingOBSERVATIONAL
Enrollment

88

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Myeloma
Interventions
OTHER

MRD Assessment

MRD assessment includes liquid biopsy and functional imaging. Liquid biopsy will be performed by the Adaptive ClonoSEQ® assay in peripheral blood. Functional imaging will be performed by whole body diffusion-weighted magnetic resonance imaging (WB-DWI).

Trial Locations (1)

10032

RECRUITING

New York Presbyterian Hospital/Columbia University Irving Medical Center, New York

Sponsors

Collaborators (1)

Hope Foundation
All Listed Sponsors
collaborator

Hope Foundation

OTHER

lead

Rajshekhar Chakraborty, MD

OTHER

NCT05625971 - Non-invasive MRD Assessment in Multiple Myeloma | Biotech Hunter | Biotech Hunter